Search Results
Your search for ,ITS matches 8694 pages
Showing 5451 - 5500Overcoming the Physical, Emotional, and Financial Effects of Cancer
Although my diagnosis of stage IIIB melanoma 5 years ago came as a shock, in hindsight, it shouldn’t have been so surprising. I had noticed a small freckle-like lesion on my upper left thigh that had become itchy and occasionally bled, but it didn’t fit the ABCDE (Asymmetry, Border irregularity,...
SABCS 2016: Neoadjuvant Abemaciclib Treatment May Benefit Patients With Early-Stage Hormone Receptor–Positive, HER2-Negative Breast Cancer
Presurgical treatment with the investigational therapeutic abemaciclib, either alone or in combination with the aromatase inhibitor anastrozole, reduced levels of Ki67, a marker of cell proliferation, in hormone receptor–positive, HER2-negative breast cancer cells, compared with anastrozole...
Valerian
Scientific Names: Valeriana officinalis, Valeriana radix Common Names: Garden valerian, Indian valerian, Pacific valerian, garden heliotrope Overview A perennial flowering plant prevalent in Europe, Asia, and North America, valerian has a long medicinal history as a relaxant. Its potential as a...
Advocacy Group to Fund $1.6 Million in Grants for 8 Early Detection Ovarian Cancer Research Projects
Tina’s Wish, a nonprofit organization dedicated exclusively to funding scientific research for the early detection of ovarian cancer, recently announced its eight 2017–2018 individual grant recipients after soliciting proposals nationally for the first time. Researchers from Dana-Farber Cancer...
Team-Based Care in Oncology: National Cancer Institute and ASCO Launch Unique Project
In its November 2016 issue, the Journal of Oncology Practice (JOP) has published a special series that represents the results of a unique project launched in 2014 by ASCO and the National Cancer Institute (NCI) to heighten awareness of ways to enhance team-based care in oncology. Concerns about...
Using Art to Humanize Medicine
Among the most widely attended sessions at the 2016 Palliative Care in Oncology Symposium in September was the keynote lecture, “Wit, Hex, Vin, Life, Death: Using Wit as a Teaching Tool,” given by Margaret Edson, author of the Pulitzer Prize–winning play Wit. Wit tells the story of an accomplished ...
Approval of Dinutuximab for High-Risk Neuroblastoma: Lessons Learned in Expediting the Development of Pediatric Cancer Drugs
On March 10, 2015, the U.S. Food and Drug Administration (FDA) granted regular approval to dinutuximab (formerly known as chimeric 14.18 antibody; Unituxin) for use in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid...
Faculty Development in Oncology: Advancing the Field by Optimizing Opportunities for Educators to Learn and Grow
In 2015, Janet Riddle, MD, and her colleagues published an article1 outlining 12 key themes for delineating how fellowship programs in medical education should be developed (See “12 Tips for Developing Successful Fellowship Programs for Medical Educators,” below.) The ASCO Post talked with Dr....
Peer-Reviewed Indian Journal of Surgical Oncology Meets Challenges, Succeeds in Developing Country
Launching a new cancer journal is a risky and arduous endeavor, especially for a specialty publication in resource-challenged countries in the developing world. To succeed, a specialty journal must publish articles from established clinical researchers that quickly garner funding and captivate its...
The Leukemia & Lymphoma Society Invests $40.3 Million in New Research to Find Cures for Hematologic Malignancies
The Leukemia & Lymphoma Society (LLS) has announced it has committed $40.3 million in new research investments to advance the most promising blood cancer science at leading academic and medical centers around the world, including Dana-Farber Cancer Institute; Weill Cornell Medicine; Memorial...
Precautions in Cancer Rehabilitation Services: Imperative or Impediment in Patient Care?
GUEST EDITOR Physiatry in Oncology explores the benefits of cancer rehabilitation in oncology practice to screen survivors for physical and cognitive impairments along the care continuum to minimize survivors’ disability and maximize their quality of life. The column is guest edited by Sean Smith, ...
AAAS Names Winship’s Dong Moon Shin, MD, as a 2016 Fellow
Dong Moon Shin, MD, the Frances Kelly Blomeyer Distinguished Endowed Chair in Cancer Research at Winship Cancer Institute of Emory University, has been named a Fellow of the American Association for the Advancement of Science (AAAS). Dr. Shin is Professor of Hematology and Medical Oncology,...
ASCO Releases Criteria for High-Quality Clinical Pathways in Oncology
ASCO recently released its Criteria for High-Quality Clinical Pathways in Oncology, a set of 15 interrelated criteria that provide an overarching framework for assessing pathway programs in the United States. ASCO developed the criteria to guide stakeholders in assessing the quality, utility, and...
NCCN Launches Campaign to Eradicate Fatal Vincristine Errors
It is uniformly fatal and impossible to undo. When the chemotherapy drug vincristine is placed in a syringe and injected intrathecally—into the spinal fluid—the patient always dies. And despite safety guidelines and labels, deaths continue to occur. Now the National Comprehensive Cancer Network®...
Complete the Free PQRS Reporting Available Through QOPI® by December 31 to Avoid a 2% Medicare Reimbursement Cut in 2018
In September 2016, ASCO announced its latest offering to oncology practices: the ability to complete all Physician Quality Reporting System (PQRS) requirements through the user-friendly Quality Oncology Practice Initiative (QOPI®) platform at no cost. By completing the PQRS module by December 31,...
Team-Based Cancer Care Explored in Special Series of Journal of Oncology Practice
The Journal of Oncology Practice (JOP) published a special series in its November issue representing the results of a unique project launched in 2014 by ASCO and the National Cancer Institute (NCI) to heighten awareness of ways to enhance team-based care in oncology. Concerns about clinician...
ASCO’s TAPUR Study Now Has More Than 100 Participants Receiving Treatment Drugs and 25 New Clinical Trial Sites
More than 100 participants are now enrolled on study drug in ASCO’s Targeted Agent and Profiling Utilization Registry (TAPUR) Study. The trial launched in March 2016 at 37 sites, and in November, it welcomed its newest participating clinical sites: Cancer Treatment Centers of America®,...
Conquer Cancer Foundation Researcher Spotlight: Dr. Priscilla Brastianos
Priscilla Brastianos, MDDirector, Central Nervous System Metastasis ProgramMassachusetts General Hospital Cancer Center, Harvard Medical School, BostonMetastatic brain cancer People are inspired to pursue careers in cancer research for any number of reasons: They might like the challenging nature...
Sodium Thiosulfate Seems to Protect Against Cisplatin-Related Hearing Loss in Children With Cancer
The antioxidant sodium thiosulfate provided protection against cisplatin-related hearing loss in children with cancer, according to a phase III trial reported by Freyer et al in The Lancet Oncology. The open-label trial included 104 assessable patients (aged 1 to 18 years) from 38 Children’s ...
A Decade of Impact: Conquer Cancer Foundation/Kidney Cancer Association Young Investigator Awards
The Kidney Cancer Association has supported 12 kidney cancer research projects through the Conquer Cancer Foundation of ASCO Young Investigator Award (YIA) program over the past decade. Early seed funding from the Kidney Cancer Association is advancing research, improving the lives of ...
ASH Launches Digital, Open-Access Journal Blood Advances at 2016 Annual Meeting
Blood has covered experimental and clinical hematologic research as the flagship journal of the American Society of Hematology (ASH). Launched officially on November 29, 2016, the open-access online journal Blood Advances will fill a niche that complements and expands on topics covered in Blood...
What’s New in Antiemesis Therapy
The optimal use of new antiemetics was the subject of a presentation at the 14th Annual School of Breast Oncology, Emory University, Atlanta, by Frankie Ann Holmes, MD, Associate Director of Breast Oncology Research at Texas Oncology, Houston. “The science of nausea and vomiting is so compelling,...
Reagan-Udall Foundation Announces Appointments of Ellen V. Sigal, PhD, and Richard L. Schilsky, MD
The Reagan-Udall Foundation for the U.S. Food and Drug Administration (FDA), an independent nonprofit organization that works to advance regulatory science to help support the scientific mission of the FDA, has elected Ellen V. Sigal, PhD, as its new Chairman, and Richard L. Schilsky, MD, as Vice ...
The FDA Ensures Quality and Safety of Generic Drugs in the United States
The U.S. Food and Drug Administration’s (FDA) generic drug program has substantially increased the availability of affordable, high-quality drugs in the United States. It is arguably the only really effective health-care cost–containment program. The more than 10,000 generic drugs currently...
NCCN Imaging Appropriate Use Criteria Published for 15 Additional Guidelines
The National Comprehensive Cancer Network® (NCCN®), a Centers for Medicare & Medicaid Services (CMS)-approved provider-led entity for imaging appropriate use criteria, continues to build its library of these standards and has published NCCN Imaging Appropriate Use Criteria™ for an additional 15 ...
Fergus J. Couch, PhD, and Max S. Wicha, MD, Recognized for Significant Contributions to Breast Cancer Research at 2016 SABCS
The American Association for Cancer Research (AACR) honored two renowned researchers for their work in breast cancer at the 2016 San Antonio Breast Cancer Symposium (SABCS), held December 6–10 in San Antonio, Texas. Fergus J. Couch, PhD, of the Mayo Clinic, will receive the 9th Annual AACR...
City of Hope’s Ravi Salgia, MD, PhD, Receives 2016 Asclepius Award From the Bonnie J. Addario Lung Cancer Foundation
City of Hope’s Ravi Salgia, MD, PhD, Chair of the Department of Medical Oncology and Therapeutics Research, has received an accolade that recognizes his decades-long dedication to treating patients with lung cancer and researching new therapies. Dr. Salgia received the 2016 Asclepius Award from...
Cancer Metastasis International Symposium Abstract Award Winners Announced
The Organizing Committee for the 7th International Cancer Metastasis International Symposium has announced the abstract award winners for the meeting. The winners will be presented during the upcoming meeting, “Cancer Metastasis Through the Lymphovascular System: Biology and Treatment,” to be held...
Randi Kaplan, LMSW, Named Schwartz Center’s 2016 National Compassionate Caregiver of the Year
The Schwartz Center for Compassionate Healthcare, a national leader in providing compassionate care to patients and caregivers, has named Randi Kaplan, LMSW, Director of the Arthur D. Emil Caregiver Support Center at Montefiore, the National Compassionate Caregiver of the Year. The prestigious...
Center for Leukemia and Lymphoma Research at UNMC Renamed Dr. James O. Armitage Center for Leukemia and Lymphoma Research
The University of Nebraska Board of Regents voted to rename an area of the University of Nebraska Medical Center (UNMC) in honor of a longtime professor who has made extraordinary contributions to the institution. The Center for Leukemia and Lymphoma Research, established in 2003, was renamed by...
Johns Hopkins Kimmel Cancer Center Expands Cancer Care and Research Facility at Sibley Memorial Hospital in Washington, DC
Cancer experts from the Johns Hopkins Kimmel Cancer Center are now embedded in a newly expanded facility within Johns Hopkins Medicine–owned Sibley Memorial Hospital in northwest Washington, DC. Sibley recently opened the 30,000-square-foot medical oncology facility—part of its new...
New Treatments for Lung Cancer in 2016
With drug approvals for immunotherapy in the first- and second-line settings, breakthroughs in targeting epidermal growth factor receptor (EGFR) mutations, and the rapid evolution of therapies that target anaplastic lymphoma kinase (ALK) rearrangements, 2016 has been an extraordinary year for lung...
Bad Year for Brain Tumors, but Still Reasons for Hope
Checkpoint inhibitors and targeted therapies are reshaping the landscape of cancer care across multiple tumor sites, but treatments for brain tumors remain decidedly unchanged. The standard of care for high-grade gliomas in the front-line setting—a combination of surgery and chemoradiation—is the...
Nivolumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
On November 10, 2016, nivolumab (Opdivo) was approved for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after platinum-based therapy.1,2 Supporting Efficacy Data Approval was based on the finding of an overall survival advantage...
Genetic Link May Explain Outcomes Differences in Multiple Myeloma in African Americans
African Americans are more than twice as likely as their white counterparts to be diagnosed with multiple myeloma, and twice as likely to die from this form of cancer. Research presented at the 9th American Association for Cancer Research (AACR) Conference on the Science of Cancer Health...
Novel Immunotherapy Combinations May Be the Future of Melanoma Treatment
The future treatment of melanoma may rely on combinations of immunotherapy agents beyond the current checkpoint inhibitors, and they are entering clinical trials, according to Jeffrey Weber, MD, PhD, Deputy Director of the Laura and Isaac Perlmutter Cancer Center at New York University Langone...
MD Anderson Cancer Center Marks 75 Years of Research to End Cancer
In November, The University of Texas MD Anderson Cancer Center celebrated its 75th anniversary with a week-long series of events that raised nearly $15 million to support its efforts in patient care and in the investigation and treatment of cancer. Housed on 16 million square feet in the city of...
Experts Consider the New Immunotherapy Paradigm in Advanced Lung Cancer
One immune checkpoint inhibitor has now moved to the front of the line for treating advanced non–small cell lung cancer (NSCLC). Based on pivotal studies presented at the 2016 European Society for Medical Oncology (ESMO) Congress, pembrolizumab (Keytruda) became a first-line option, and it is...
‘Clinically Useful’ Findings for Brentuximab Vedotin in CTCL, Rituximab Maintenance in MCL
Positive studies about brentuximab vedotin (Adcetris) in cutaneous T-cell lymphoma1 and rituximab (Rituxan) maintenance therapy in mantle cell lymphoma (MCL)2 were reported at the 2016 Annual Meeting of the American Society for Hematology (ASH). “These abstracts each focus on approved agents and...
Medicare Access and CHIP Reauthorization Act: The Final Rule
It is gratifying to see the Centers for Medicare & Medicaid Services (CMS) does listen to public comments regarding new proposals. Since CMS opened the comment period for its Quality Payment Program, which repeals the Sustainable Growth Rate Formula and was proposed to implement the Medicare...
ASH 2016: New Data Shed Light on Potential Advantages of Pacritinib for Patients With Myelofibrosis
Compared with standard therapy, pacritinib significantly reduces spleen size among people with myelofibrosis who have very low levels of platelets, according to a late-breaking study presented by Mascarenhas et al during the 58th American Society of Hematology (ASH) Annual Meeting & Exposition...
ASH 2016: Ibrutinib Found Helpful in Treating Graft-vs-Host Disease After Stem Cell Transplant
A late-breaking abstract presented by Miklos et al during the 58th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego (Abstract LBA-3) showed patients who experience graft-vs-host disease (GVHD) after stem cell transplantation that is not resolved by corticosteroid...
ASH 2016: Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia Patients With Deep Molecular Response
In one of the largest-ever trials to assess the safety of stopping tyrosine kinase inhibitor therapy—the Euro-Ski trial—about half of 821 patients with chronic myeloid leukemia (CML) showed no evidence of relapse 2 years after treatment cessation, suggesting that some patients can...
ASH 2016: Biomarker May Predict Which Patients Previously Treated for Cancer Will Develop Highly Fatal Form of Leukemia
Patients successfully treated for breast, colon, and other cancers can go on to develop an often-fatal form of leukemia, sometimes years after completion of treatment, due to a genetic mutation leading to secondary malignancies known as therapy-related myeloid neoplasms. A study conducted by...
FDA Grants sBLA to Pembrolizumab for the Treatment of Relapsed or Refractory Classical Hodgkin Lymphoma
The U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for pembrolizumab (Keytruda), an anti–programmed cell death protein 1 (PD-1) therapy, for the treatment of patients with refractory classical Hodgkin lymphoma or for...
Outreach to Patients With Cirrhosis Doubles Early Screening Rates for Liver Cancer
Proactive outreach to cirrhosis patients in a safety net health system successfully doubled their screening rates for liver cancer, UT Southwestern Medical Center researchers found in a study published by Singal et al in Gastroenterology. Cirrhosis patients are at high risk to develop liver...
FDA Grants Full Approval and Label Update for Ponatinib in CML and ALL
The U.S. Food and Drug Administration (FDA) has granted ponatinib (Iclusig) full approval for the treatment of adult patients with chronic-phase, accelerated-phase, or blast-phase chronic myeloid leukemia (CML) or Philadelphia chromosome–positive acute lymphoblastic leukemia (ALL) for whom no ...
FDA Grants Priority Review to Pembrolizumab for New Indication in Microsatellite Instability–High Cancer
On November 28, the U.S. Food and Drug Administration (FDA) accepted for review the supplemental Biologics License Application (sBLA) for pembrolizumab (Keytruda) for the treatment of previously treated patients with advanced microsatellite instability–high (MSI-H) cancer. The FDA granted...
NCCN Imaging Appropriate Use Criteria Published for 15 Additional Guidelines
The National Comprehensive Cancer Network® (NCCN®), a Centers for Medicare & Medicaid Services (CMS)-approved provider-led entity for imaging appropriate use criteria, continues to build its library of these standards and has published NCCN Imaging Appropriate Use Criteria™ for an ...
ASH Honors J. Evan Sadler, MD, PhD, and Ayalew Tefferi, MD, With the 2016 Henry M. Stratton Medal
The American Society of Hematology (ASH) will recognize J. Evan Sadler, MD, PhD, of Washington University School of Medicine in St. Louis, and Ayalew Tefferi, MD, of Mayo Clinic College of Medicine, with the 2016 Henry M. Stratton Medal for their seminal contributions in the areas of basic and...
